MolecularMD Icon Acquires MolecularMD MolecularMD is expected to expand Icon's laboratory services by enabling it to better support precision medicine programs for drug-diagnostic codevelopment. FDA CDx Class Labeling Draft Guidance May Ease Patient Access, Spur Competition Among Test Makers Premium The draft guidelines have intrigued industry players interested in pursuing labeling that would allow their CDx to direct treatment for a class of drugs instead of one drug. Sysmex, MolecularMD to Collaborate for CDx Development, Commercialization The firms said they will integrate their capabilities and competencies to offer solutions to global pharmaceutical customers. Health Canada Approves Two BCR-ABL Tests The tests from Asuragen and MolecularMD are designed for use in chronic myeloid leukemia patients, including those receiving tyrosine kinase inhibitor therapy. In Brief This Week: MolecularMD, Agendia, Promega, NRGene, More This week's news includes MolecularMD, Agendia, Promega, and NRGene. Jun 4, 2018 MolecularMD, Genoptix Ink Marketing Agreement for CDx to Novartis CML Drug Dec 27, 2017 MolecularMD Gets FDA Authorization for Companion Dx to Novartis CML Drug Nov 14, 2017 MolecularMD to Offer Promega Microsatellite Instability Technology Feb 16, 2017 MolecularMD, Asterand Bioscience Form Biomarker Alliance Sep 15, 2016 NYU Team to Validate ddPCR Liquid Biopsy for Monitoring Metastatic Melanoma Recurrence Premium Jun 27, 2016 Illumina, MolecularMD Agree to Collaborate on Sequencing-Based Companion Diagnostics Jun 2, 2016 Definiens, MolecularMD Partner to Provide Quantitative Tissue Assays for Oncology Apr 25, 2016 MolecularMD Gets CE Mark for CDx Assay Used in Daiichi Sankyo Clinical Trial Jul 16, 2015 MolecularMD Lands NY State Approval for Notch 1 Mutation Test Dec 18, 2014 MolecularMD Receives CAP Accreditation for Cambridge NGS Laboratory Apr 4, 2014 MolecularMD Receives CLIA Certification for Second Lab Feb 26, 2014 New Tests for Minimal Residual Disease Signal Growing Importance of Prognostic Tools in Leukemia Premium Feb 19, 2014 MolecularMD, Novartis to Develop Test to Monitor Treatment-Free Remission for CML Drug Trial Nov 6, 2013 Ariad Stops Iclusig Sales Due to Serious AEs; Would a CDx Have Changed Risk/Benefit Profile? Premium Oct 25, 2013 PGDx, MolecularMD Ink Co-Marketing Deal Jul 31, 2013 MDx/CDx Focus: MolecularMD Gains Exclusive Rights to Develop DDR2 Tests; NeoGenomics' MDS Tests Premium Jul 29, 2013 MolecularMD Licenses DDR2 Markers for Assay Development May 30, 2013 MolecularMD Licenses Rights to Commercialize Technology Aimed at Endometrial Cancer Jan 30, 2013 MDx/CDx Focus: MolecularMD Grabs LKB1 Rights; Clarient Offering Qiagen KRAS Test; Inform's OnPART Premium Jan 28, 2013 MolecularMD Licenses LKB1 Marker for Lung Cancer Assay Development Load More Breaking News Sequencing Study Uncovers MERS-Related Coronavirus in Swiss Bats Angstrom Bio Raises $3M in Private Financing Eagle Biosciences, Genetic Analysis Ink Distribution Agreement for Gut Microbiota Test Centogene Q1 Revenues Grow More Than Fivefold Driven by COVID-19 Testing Epizyme Partnering With Quest Diagnostics for Lymphoma Mutation Testing Enzo Biochem, CLX Health Partner to Support COVID-19 Testing for International Travel The Scan CDC Calls Delta "Variant of Concern" CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern." From FDA to Venture Capital Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post. Consent Questions Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles. Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.